EL DORADO HILLS, Calif., June 13, 2006 /PRNewswire via COMTEX/ -- NutraCea (NTRZ) , a leader in stabilized rice bran research and technology, announced today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office. The original patent application was previously approved in the United States and in Europe in 2001 by the United States Patent and Trademark Office under patent # 6303586 B1. Additionally, the patent application has been approved in Korea by the Korean Intellectual Property office under patent # 10-2000-7002174. The Mexican patent has been issued to the RiceX Company, a wholly owned subsidiary of NutraCea. The Mexican patent number is # 232655.
The patent describes a treatment method for diabetes with 11 claims, including reducing glycosylated hemoglobin and improving synthesis of insulin in diabetic subjects by ingesting stabilized rice bran derivatives produced by NutraCea.
Efficacy of the NutraCea products was tested in a clinical study and review completed by Advanced Medical Research Center at Madison, Wisconsin. The results of this study were published in the March 2002 issue of the Journal of Nutritional Biochemistry that one out of four diabetics taking part in a 57-subject study were able to reduce their daily injection of insulin or medication dosages up to 30% after adding stabilized rice bran products to their diets.
Brad Edson, CEO of NutraCea, stated, "We are pleased to receive Mexican approval of our patent application, which supports the use of stabilized rice bran as a means of therapy for those suffering from diabetes, hyperglycemia and hypoglycemia. This additional patent approval has enabled NutraCea to build on its patent portfolio among numerous countries, adding validity to the many benefits stabilized rice bran has to offer. As this patent portfolio continues to expand, it creates international protection for our proprietary stabilized rice bran, which will help support the marketability of our offerings to our customers."
NutraCea, under patents and "trade secrets protection," has commercialized the process for its products and currently markets these products under such trade names as Solubles, RiSolubles and Rice Mucil.
NutraCea is a world leader in stabilized rice bran technology. Through its wholly owned subsidiary RiceX, the Company manufacturers as well as distributes products and food ingredients made from rice bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.
Forward Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the pending matters considered by the Company may not proceed as contemplated and the matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward- looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.